Familial cold autoinflammatory syndrome with rheumatoid arthritis

Walterscheid, Brooke; Nguyen, Jeannie; Gadwala, Swetha; Shome, G.P.; Tarbox, Michelle; Tarbox, James

doi:10.1080/08998280.2021.1913042

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Особенностями течения этого субтипа РА были резистентность к терапии БПВП и ингибиторами ФНО-α и хороший клинический эффект на фоне лечения колхицином (ингибитор ИЛ-1) и анакинрой. Описана ассоциация РА с криопирин-ассоциированным периодическим синдромом [296].…”

Section: таблица 3 системные аутовоспалительные заболевания: общая ха...unclassified

See 1 more Smart Citation

The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)

Насонов

Samsonov

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

According to modern concepts, human immune-mediated inflammatory diseases (IMIDs), depending on the prevailing mechanisms of immunopathogenesis, are divided into two main categories – autoimmune and autoinflammatory.At the same time, both autoimmune and autoinflammatory mechanisms are involved in the pathogenesis of most IMIDs, the complex interaction of which is reflected in the polymorphism of clinical manifestations, course variants, outcomes, and therapy efficacy. It is assumed that hyperproduction of cytokines of the interleukin (IL) 1 family, which is one of the key regulators of innate immunity, determines the “crossover” between the mechanisms of autoinflammation and autoimmunity in IMIDs. Anakinra is currently used in clinical practice to suppress the pathological effects of IL-1. An analysis of the results of the clinical use of Anakinra indicates that treatment with this drug should be considered as a promising direction in the pharmacotherapy of systemic autoinflammatory diseases (SAIDs) and critical conditions in children and adults associated with the development of hyperinflammation. The main directions of the Anakinra clinical research program are presented, including: determining the place of the drug in the implementation of the "Treat to Target" strategy and personalization of therapy, primarily in patients with “resistant” (difficult-to-treat) subtype of rheumatoid arthritis and comorbid pathology, as well as with severe forms of microcrystalline arthritis; the possibility of using Anakinra to improve the early diagnosis of SAIDs in children and adults; creation of the Russian register of patients with SAIDs, who are potentially indicated for treatment with Anakinra.

show abstract

Section: таблица 3 системные аутовоспалительные заболевания: общая ха...unclassified

“…Научно-практическая ревматология. 2022;60(3):[280][281][282][283][284][285][286][287][288][289][290][291][292][293][294][295][296][297][298] …”

unclassified

The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)

Насонов

Samsonov

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Familial cold autoinflammatory syndrome with rheumatoid arthritis

Cited by 1 publication

References 13 publications

The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)

The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)

Contact Info

Product

Resources

About